All Information (Except Text) for H.R.5247 - Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2018115th Congress (2017-2018)

---

03/21/2018 Passed/agreed to in House: On passage Passed by recorded vote: 267 - 149 (Roll no. 121).(text: CR H1738-1739)

03/13/2018 Failed of passage/not agreed to in House: On motion to suspend the rules and pass the bill Failed by the Yeas and Nays: (2/3 required): 259 - 140 (Roll no. 102).

03/13/2018 Introduced in House

---

04/09/2018 Read the second time. Placed on Senate Legislative Calendar under General Orders. Calendar No. 367.

03/23/2018 Read the first time. Placed on Senate Legislative Calendar under Read the First Time.

03/22/2018 Received in the Senate.

03/21/2018 Motion to reconsider laid on the table Agreed to without objection.

03/21/2018 On passage Passed by recorded vote: 267 - 149 (Roll no. 121). (text: CR H1738-1739)

03/21/2018 On motion to recommit with instructions Failed by the Yeas and Nays: 182 - 233 (Roll no. 120).

03/21/2018 Considered as unfinished business. (consideration: CR H1748-1750)

03/21/2018 POSTPONED PROCEEDINGS - At the conclusion of debate on the Pallone motion to recommit with instructions, the Chair put the question on the motion and by voice vote announced that the ayes had prevailed. Mr. Pallone demanded the yeas and nays, and the Chair postponed further proceedings on the motion to recommit until later in the legislative day.

03/21/2018 The previous question on the motion to recommit with instructions was ordered without objection.

03/21/2018 DEBATE - The House proceeded with 10 minutes of debate on the Pallone motion to recommit with instructions. The instructions contained in the motion seek to report the same back to the House forthwith with an amendment to require the Food and Drug Administration (FDA) to issue guidance describing how the agency will use expanded access outcomes when considering and evaluating investigational products for full approval. Additionally, the motion seeks to provide liability protection to manufacturers, physicians, and hospitals offering a product under expanded access, as long as the entity is in compliance with current federal law, and it also increases transparency in the FDAs expanded access program.

03/21/2018 Mr. Pallone moved to recommit with instructions to the Committee on Energy and Commerce. (text: CR H1746-1747)

03/21/2018 The previous question was ordered pursuant to the rule.

03/21/2018 DEBATE - The House proceeded with one hour of debate on H.R. 5247.

03/21/2018 The resolution provides for one hour of debate on each bill. The resolution makes in order only the further amendment to H.R. 4566 printed in the report. No further amendments on either bill are made in order. Section 3 of the resolution makes it in order to consider any resolution reported from the Rules Committee on the day it is reported through the legislative day of March 23, 2018. Section 4 grants suspension authority on the legislative days of March 22, 2018 and March 23, 2018. Section 5 of the resolution amends section 3(a) of H. Res. 5.

03/21/2018 Considered under the provisions of rule H. Res. 787. (consideration: CR H1738-1748)

03/20/2018 Rule H. Res. 787 passed House.

03/19/2018 Rules Committee Resolution H. Res. 787 Reported to House. The resolution provides for one hour of debate on each bill. The resolution makes in order only the further amendment to H.R. 4566 printed in the report. No further amendments on either bill are made in order. Section 3 of the resolution makes it in order to consider any resolution reported from the Rules Committee on the day it is reported through the legislative day of March 23, 2018. Section 4 grants suspension authority on the legislative days of March 22, 2018 and March 23, 2018. Section 5 of the resolution amends section 3(a) of H. Res. 5.

03/16/2018 Referred to the Subcommittee on Health.

03/13/2018 On motion to suspend the rules and pass the bill Failed by the Yeas and Nays: (2/3 required): 259 - 140 (Roll no. 102).

03/13/2018 Considered as unfinished business. (consideration: CR H1528-1529)

03/13/2018 At the conclusion of debate, the Yeas and Nays were demanded and ordered. Pursuant to the provisions of clause 8, rule XX, the Chair announced that further proceedings on the motion would be postponed.

03/13/2018 DEBATE - The House proceeded with forty minutes of debate on H.R. 5247.

03/13/2018 Considered under suspension of the rules. (consideration: CR H1521-1527; text of measure as introduced: CR H1521-1522)

03/13/2018 Mr. Walden moved to suspend the rules and pass the bill.

03/13/2018 Referred to the House Committee on Energy and Commerce.

03/13/2018 Introduced in House